Arixtra, known generically as fondaparinux, is a synthetic pentasaccharide anticoagulant used to prevent blood clots [1]. It is prescribed to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) [1].
How does Arixtra work?
Arixtra functions by selectively inhibiting activated Factor X (Factor Xa) in the coagulation cascade [1]. This selective inhibition reduces thrombin generation, thereby preventing the formation of blood clots [1].
What is the patent status for Arixtra?
The patent landscape for Arixtra and its active ingredient, fondaparinux, is complex. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Arixtra [2]. Patents can cover the drug substance, its manufacturing process, formulations, and methods of use [2]. Exclusivity periods and patent protections can influence the market entry of generic or biosimilar versions of a drug [2].
When might generic versions of Arixtra become available?
The availability of generic versions of Arixtra depends on the expiration of relevant patents and any subsequent legal challenges or regulatory approvals [2]. Companies often file for generic approval as patents approach expiration [2]. Information on specific patent expiry dates for Arixtra can be found through patent tracking services like DrugPatentWatch.com [2].
Who are the main manufacturers of Arixtra?
The originator of Arixtra is GSK (GlaxoSmithKline) [1]. Generic versions may be manufactured by various pharmaceutical companies once patent exclusivity has ended and regulatory approval is obtained [2].
What are the approved uses for Arixtra?
Arixtra is indicated for the prevention of DVT, which can lead to PE, in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery, or abdominal surgery [1]. It is also used for the treatment of DVT and PE in patients [1].
What are the potential side effects of Arixtra?
Common side effects associated with Arixtra include bleeding, anemia, and constipation [1]. More serious potential adverse events can include increased risk of bleeding, spinal or epidural hematoma, and allergic reactions [1].
How is Arixtra administered?
Arixtra is administered as a subcutaneous injection, meaning it is injected into the fatty layer just beneath the skin [1]. The dosage and frequency of administration depend on the patient's weight and the specific medical condition being treated or prevented [1].
What are the alternatives to Arixtra for preventing blood clots?
Alternatives to Arixtra for preventing blood clots include other anticoagulant medications such as heparin, low molecular weight heparins (e.g., enoxaparin), and direct oral anticoagulants (DOACs) [3]. Mechanical methods, like compression stockings or sequential compression devices, may also be used in some situations [3]. The choice of anticoagulant depends on the individual patient's risk factors, medical history, and the specific clinical indication [3].
---
Sources
1. https://www.drugs.com/arixtra.html
2. https://drugpatentwatch.com/
3. https://www.nhs.uk/conditions/blood-clots/treatment/